Thus, we hypothesized that the pro-inflammatory properties of IFN-γ therapy could prime an effective anti-tumor response, and that adding a PD-1 pathway-targeted monoclonal antibody (mAb) would ablate the associated inhibitory impacts of PD-L1 upregulation to facilitate more robust and sustained T-cell mediated tumor cell destruction. This evidence concerns the gene IFNG and neoplasm.